Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).

Full DD Report for ALNY

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALNY)

Alnylam: Analysts See A Comet On The Rise
Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNY’s focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- ...
Source: SeekingAlpha
Date: September, 06 2018 15:01
A Second Look At Inotersen's Approval Potential
Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Last week, Io...
Source: SeekingAlpha
Date: September, 04 2018 17:46
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516...
Source: SeekingAlpha
Date: September, 01 2018 05:42
Over-Extrapolation Of Pfizer Cardiomyopathy Data Creates Buying Opportunity For Eidos
Pfizer ( PFE ) just announced the results for their Phase 3 ATTR-CM trial at the ESC Congress 2018. Pfizer reported a 30% reduction in the risk of all-cause mortality and a 32% reduction in the rate of CV-related hospitalization with tafamidis compared with placebo. The data can be found in ...
Source: SeekingAlpha
Date: August, 30 2018 10:00
Alnylam's patisiran OK'd in Europe for hATTR amyoidosis
The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,...
Source: SeekingAlpha
Date: August, 30 2018 07:42
FDA OK's Bayer's Jivi for hemophilia A
The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, ...
Source: SeekingAlpha
Date: August, 30 2018 07:37
Alnylam Receives Approval of ONPATTRO(TM) (patisiran) in Europe
– ONPATTRO Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy – – First-Ever RNAi Therapeutic Approved in the European Union (EU) – Alnylam Pharmace...
Source: Business Wire
Date: August, 30 2018 07:00
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5, 2018 at 10:15 am ET at the We...
Source: Business Wire
Date: August, 29 2018 09:00
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals, Inc. and Opiant Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 29, 2018 / U.S. equities rallied on Tuesday as consumer confidence hits an eighteen-year high and optimism over new proposed trade agreement between U.S. and Mexico continue to push broader markets higher. Consumer confidence increased from 127.9 in July t...
Source: ACCESSWIRE IA
Date: August, 29 2018 08:00
Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease
Novel drugs that are shown to improve survival in patients with a lethal condition quickly become standard of care for that condition. The ATTR-ACT Study sponsored by Pfizer ( PFE ) and published in Monday's issue of NEJM includes survival curves for TTR (transthyretin-related) amyloid heart...
Source: SeekingAlpha
Date: August, 28 2018 14:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08112.00109.00113.55108.74773,059
2018-05-17101.33101.64102.42100.02865,688
2017-06-2078.9681.3884.181778.331,033,221
2017-06-1976.8079.0582.3176.451,306,879
2017-06-1675.8276.0776.2474.4851,264,505

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1235,43861,00858.0875Short
2018-12-1195,665119,16780.2781Short
2018-12-1090,448127,78270.7831Short
2018-12-07147,157267,85154.9399Short
2018-12-06106,456181,73858.5766Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALNY.


About Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Logo for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Not available

 

Contact Information

 

 

Current Management

  • John M. Maraganore / President, CEO

Current Share Structure

  • Market Cap: $10,366,876,246 - 05/14/2018
  • Issue and Outstanding: 100,522,411 - 04/30/2018

 


Recent Filings from (NASDAQ: ALNY)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ALNY)

Daily Technical Chart for (NASDAQ: ALNY)


Stay tuned for daily updates and more on (NASDAQ: ALNY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALNY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALNY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALNY and does not buy, sell, or trade any shares of ALNY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/